GURU.Markets stock price, segment price, and overall market index valuation
The company's share price ORIC Pharmaceuticals
ORIC Pharmaceuticals is a biotech company focused on overcoming drug resistance in cancer treatment. Its stock price represents a venture capital bet on the success of its scientific developments. The chart reflects high volatility and dependence on clinical trial data.
Share prices of companies in the market segment - Oncology targeted therapy
ORIC is an oncology company developing drugs to overcome resistance to hormonal cancer therapy. We classify it as part of the Oncology Targeted Therapy sector, and the chart below reflects the dynamics of this entire segment, driven by news of clinical trials and scientific breakthroughs.
Broad Market Index - GURU.Markets
ORIC Pharmaceuticals is an oncology company developing drugs to overcome resistance to hormone therapy in cancer treatment. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how ORIC shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ORIC - Daily change in the company's share price ORIC Pharmaceuticals
For ORIC Pharmaceuticals, an oncology company, change_co is a measure of the sector's inherently high volatility. Each daily change reflects sensitivity to clinical trial news. This metric isn't just noise, but a critical component of the models at System.GURU.Markets that assess risk in innovative medicine.
Daily change in the price of a set of shares in a market segment - Oncology targeted therapy
ORIC Pharmaceuticals, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with ORIC's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
ORIC is a biopharmaceutical company developing targeted therapies for cancer. Oncology is a highly volatile sector driven by clinical trial results. The chart below reflects average fluctuations in this industry, providing context for evaluating ORIC stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization ORIC Pharmaceuticals
ORIC is a biotech company specializing in the development of targeted therapies for cancer treatment. Its shares are buoyed by anticipation of clinical trial results. These sharp movements are part of a complex mosaic of stock market volatility.
Annual dynamics of market capitalization of the market segment - Oncology targeted therapy
ORIC Pharmaceuticals, Inc. is a clinical-stage biotech company developing drugs to overcome resistance to cancer treatments. Its stock price is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this complex area of oncology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
ORIC Pharmaceuticals is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization ORIC Pharmaceuticals
ORIC, a biotech company focused on overcoming cancer treatment resistance, has sharp monthly fluctuations reflecting the release of clinical trial data, which is key to its valuation.
Monthly dynamics of market capitalization of the market segment - Oncology targeted therapy
Biotechnologies focused on combating cancer resistance are a field of high risk and great promise. The dynamics of this sector, as seen in the chart, reflect the volatility typical of oncology development. This is the context in which companies like ORIC Pharmaceuticals conduct their science-intensive research.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
ORIC Pharmaceuticals is a clinical-stage oncology company. Its shares exist in a world of their own: their price rises and falls based on trial data, paying little attention to overall market trends. The chart illustrates this disconnect from general sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization ORIC Pharmaceuticals
For ORIC Pharmaceuticals, a clinical-stage oncology company, weekly performance reflects expectations for its research. Any announcements of new trials, data releases, or news from competitors in the targeted therapy field can trigger sharp stock price movements.
Weekly dynamics of market capitalization of the market segment - Oncology targeted therapy
ORIC Pharmaceuticals shares, like those of the entire oncology biotech sector, are driven by sector-wide news and sentiment. Breakthroughs in targeted therapies or changes in FDA policy could boost the entire industry. The chart will show how the company stacks up against this high-risk segment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Biotech companies like ORIC Pharmaceuticals often exist in their own world, isolated from broader market fluctuations. The fate of their stocks is determined not by inflation reports, but by clinical trial results. This chart shows how often unique company news allows its shares to move against the broader market tide.
Market capitalization of the company, segment and market as a whole
ORIC - Market capitalization of the company ORIC Pharmaceuticals
The ORIC Pharmaceuticals market capitalization chart represents the financial valuation of a biotech company focused on overcoming cancer treatment resistance. It reflects investor expectations for its scientific developments in oncology. Its speculative dynamics tell the story of how the market evaluates the potential of early clinical trials in one of the most complex areas of medicine.
ORIC - Share of the company's market capitalization ORIC Pharmaceuticals within the market segment - Oncology targeted therapy
ORIC Pharmaceuticals is an oncology company focused on developing drugs to overcome resistance to cancer treatments. Its position in the biotech sector is based on this important scientific approach. The chart shows how the market assesses its chances of developing drugs that will restore the effectiveness of therapy.
Market capitalization of the market segment - Oncology targeted therapy
ORIC Pharmaceuticals is focused on overcoming drug resistance in cancer treatment. The chart below shows the total market capitalization of the targeted oncotherapy sector, reflecting the massive investment in the fight against cancer. In this race, ORIC is working on one of the most complex and important problems.
Market capitalization of all companies included in a broad market index - GURU.Markets
Oncology is a field where biotechnology, as seen in the chart, is creating enormous value. ORIC Pharmaceuticals focuses on developing drugs to overcome resistance to cancer treatments. Its capitalization is a risky bet on its scientific hypotheses and the ability to solve one of the main problems in cancer treatment.
Book value capitalization of the company, segment and market as a whole
ORIC - Book value capitalization of the company ORIC Pharmaceuticals
ORIC Pharma's book value represents capital invested in the fight against cancer resistance. At the clinical trial stage, its assets are primarily cash from investors. The chart shows the financial reserves the company is investing in developing drugs that can overcome tumor resistance.
ORIC - Share of the company's book capitalization ORIC Pharmaceuticals within the market segment - Oncology targeted therapy
ORIC Pharmaceuticals, an oncology company, focuses its resources on research. Its share of the sector's tangible assets consists of cutting-edge laboratories. The graph shows that at this stage, its value is created in scientific research, not in large-scale production.
Market segment balance sheet capitalization - Oncology targeted therapy
ORIC Pharmaceuticals is an oncology company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. ORIC focuses on drug development, and its capital is intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
ORIC Pharmaceuticals is a biopharmaceutical company focused on overcoming cancer treatment resistance. Its book value is derived from the capital invested in clinical trials of its drug candidates. This provides the financial foundation for tackling one of the major challenges in oncology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - ORIC Pharmaceuticals
ORIC Pharmaceuticals is an oncology biotech company. Its book value is its cash. Its entire market capitalization is a premium to this cash, representing investors' bet on the success of its clinical trials.
Market to book capitalization ratio in a market segment - Oncology targeted therapy
ORIC Pharmaceuticals is focused on developing drugs to treat treatment-resistant cancer. Like many biotech companies, its market value is based on expectations for future drugs. The chart shows the significant premium investors place on its scientific potential compared to its current tangible assets.
Market to book capitalization ratio for the market as a whole
ORIC Pharmaceuticals is a biotech company focused on overcoming cancer treatment resistance. This chart reflects the average market valuation. Its high premium, therefore, is entirely based on investors' faith in the scientific potential of its developments and the potential for breakthrough treatments.
Debts of the company, segment and market as a whole
ORIC - Company debts ORIC Pharmaceuticals
ORIC Pharmaceuticals is a biotech company focused on developing targeted therapies for cancer treatment. Being in clinical trials, the company does not generate revenue and relies entirely on investments. This chart shows how ORIC manages its capital to finance long and expensive programs to develop new anticancer drugs.
Market segment debts - Oncology targeted therapy
ORIC Pharmaceuticals is a biotech company focused on developing treatments for treatment-resistant cancer. Currently in clinical trials, the company has no revenue and incurs significant R&D expenses. Debt is unusual at this stage. This chart reflects its financial position and ability to fund its research activities.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio ORIC Pharmaceuticals
ORIC Pharmaceuticals is a biotech company focused on developing cancer drugs. This chart shows its financing structure. For a company without stable sales revenue, any debt is a significant risk. It reflects creditors' faith in the company's scientific potential, but also vulnerability if clinical trials fail to yield the expected results.
Market segment debt to market segment book capitalization - Oncology targeted therapy
ORIC Pharmaceuticals is focused on developing treatments for cancers resistant to existing therapies. This field requires lengthy and expensive clinical trials. This chart shows the collective debt burden in the biotech sector. It helps assess how ORIC funds its research and how its capital raising strategy compares to the industry.
Debt to book value of all companies in the market
ORIC Pharmaceuticals is a biopharmaceutical company focused on developing cancer therapies. Being in clinical trials, ORIC has no stable revenue and relies on external funding. This chart helps assess the company's options—shareholder dilution or debt financing—in the current market environment.
P/E of the company, segment and market as a whole
P/E - ORIC Pharmaceuticals
For ORIC Pharmaceuticals, a clinical-stage oncology company, the P/E ratio is not a useful metric because it has no sales revenue. Any values on this chart are random. Investors evaluate the company solely on the potential of its scientific developments and the likelihood of success of future cancer drugs.
P/E of the market segment - Oncology targeted therapy
ORIC Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer resistant to existing therapies. The company is in clinical trials. This chart shows the average valuation for the oncology biotech sector, reflecting investor expectations for this high-risk but promising field.
P/E of the market as a whole
ORIC Pharmaceuticals is a biotech company focused on developing drugs to overcome resistance to cancer treatments. Its valuation is a pure bet on the success of its scientific hypotheses and clinical trials. Overall market sentiment, reflected in this chart, is completely irrelevant. ORIC's fate is decided in the lab, not on the stock market.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company ORIC Pharmaceuticals
ORIC Pharmaceuticals is a biotech company focused on developing drugs to treat cancer resistant to existing therapies. Its value is determined by the potential of its research and development pipeline. This chart shows how much investors believe in the success of its clinical programs, valuing the company based on projected future revenues from potential breakthrough drugs.
%20P%2FE%20ORIC%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-ORIC-Pharmaceuticals&v=1772559326817 "Chart of the company's future (projected) P/E ORIC Pharmaceuticals")
Future (projected) P/E of the market segment - Oncology targeted therapy
ORIC Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer resistant to existing therapies. The chart reflects average profitability expectations for the oncology segment. ORIC's position on this indicator reflects investors' bet that its scientific developments will overcome resistance and create new treatment standards.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-targeted-therapy&v=1772559326832 "Future (projected) P/E graph of the market segment - Oncology targeted therapy")
Future (projected) P/E of the market as a whole
ORIC Pharmaceuticals is a biotech company focused on developing treatments for treatment-resistant cancers. Its valuation is based almost entirely on future expectations. This chart shows the overall risk tolerance of investors. In an optimistic market environment, funding for such long-term research projects becomes more accessible.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772559326848 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit ORIC Pharmaceuticals
ORIC Pharmaceuticals is a biotech company focused on developing treatments for cancer resistant to existing therapies. Currently, its financial results, as reflected in the chart, primarily consist of research and clinical trial expenses. Profitability will only be realized once its drugs are approved and launched.
Profit of companies in the market segment - Oncology targeted therapy
ORIC Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer resistant to existing therapies. Its future depends on the success of clinical trials. This chart shows the overall profitability of the oncology development sector. It reflects the overall investment attractiveness of this area and progress in the fight against the most complex forms of cancer.
Overall market profit
ORIC Pharmaceuticals is focused on developing drugs for resistant forms of cancer, which requires lengthy and capital-intensive research. Overall market conditions, reflected in corporate earnings trends, are critical for biotech companies. During periods of growth, investors are more willing to fund risky research, giving ORIC the opportunity to develop breakthrough drugs.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company ORIC Pharmaceuticals
ORIC Pharmaceuticals is a biotechnology company focused on developing drugs to overcome resistance to cancer treatments. Future profits are entirely dependent on the success of its clinical programs. This chart shows analysts' speculative expectations regarding the breakthrough potential of ORIC's research and developments and their future commercial value.
%20profit%20of%20the%20company%20ORIC%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-ORIC-Pharmaceuticals&v=1772559326923 "Graph of future (projected) profit of the company ORIC Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Oncology targeted therapy
ORIC Pharmaceuticals focuses on developing innovative treatments for cancer resistant to existing therapies. The company's future depends entirely on the success of clinical trials and regulatory approval. The chart below reflects general profitability forecasts for the biotech sector, allowing one to assess ORIC's significant potential and risks relative to the broader industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-targeted-therapy&v=1772559326935 "Graph of future (predicted) profits of companies in a market segment - Oncology targeted therapy")
Future (predicted) profit of the market as a whole
ORIC Pharmaceuticals is a biotech company focused on developing cancer drugs. Its current value is determined not by revenue, but by the potential of its research and development and the results of clinical trials. Therefore, its performance is weakly correlated with overall economic trends, as illustrated by this corporate earnings chart.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772559326937 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - ORIC Pharmaceuticals
ORIC Pharmaceuticals is a biotech company focused on developing drugs for treatment-resistant cancer. Despite minimal current revenue, this chart shows the enormous advance the market is making on its research. The metric's dynamics effectively reflect investors' bets on the success of clinical trials and a future blockbuster.
P/S market segment - Oncology targeted therapy
ORIC Pharmaceuticals is a biotech company focused on developing targeted therapies for the treatment of cancer resistant to other treatments. Future revenue depends on the success of its drugs. This chart, showing the average valuation for oncology companies, helps assess investor expectations for ORIC's scientific platform and developments relative to the sector.
P/S of the market as a whole
ORIC Pharmaceuticals is a biotech company focused on developing treatments for cancer resistant to existing therapies. Like many companies in the research stage, its current revenue is minimal. This market revenue valuation chart is important for understanding how much expectations for future advances in oncology influence the company's current valuation.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company ORIC Pharmaceuticals
ORIC Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer resistant to existing therapies. Its future revenue is entirely dependent on the success of its research. This chart shows how the market evaluates ORIC's scientific potential, betting on its drug candidates successfully completing clinical trials and reaching the market.
%20P%2FS%20ORIC%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-ORIC-Pharmaceuticals&v=1772559326974 "The graph of the company's future (projected) P/S ORIC Pharmaceuticals")
Future (projected) P/S of the market segment - Oncology targeted therapy
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on overcoming drug resistance in oncology. The company's valuation, which has no commercial products, is based solely on investors' faith in its scientific approach and the potential of its candidates to address one of the biggest challenges in cancer treatment, which carries high risks.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-targeted-therapy&v=1772559326982 "Future (projected) P/S market segment graph - Oncology targeted therapy")
Future (projected) P/S of the market as a whole
ORIC Pharmaceuticals is a clinical-stage biotech company focused on cancer treatment. Its prospects depend on the success of its research. In the context of the overall revenue projections shown in the chart, ORIC represents a venture capital investment in the future of oncology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772559326995 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales ORIC Pharmaceuticals
ORIC Pharmaceuticals is a biotech company focused on overcoming drug resistance in cancer treatment. As a clinical-stage company, its revenue, if present, is likely generated through upfront fees and milestone payments from collaborations with major pharmaceutical partners.
Sales of companies in the market segment - Oncology targeted therapy
ORIC Pharmaceuticals (ORIC) is a biopharmaceutical company focused on developing treatments for cancer resistant to existing therapies. It creates drugs that overcome tumor resistance. This metric reflects the company's total revenue in the oncology sector, where ORIC operates at the forefront of science, addressing one of the most complex challenges in medicine.
Overall market sales
ORIC Pharmaceuticals is a biotech company focused on developing drugs to treat cancer resistant to existing treatments. While its success depends on science, the overall economic situation, reflected in this chart, plays a role in attracting investment. Economic growth creates a favorable environment for funding risky but potentially breakthrough research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company ORIC Pharmaceuticals
ORIC Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer resistant to existing therapies. The company's future revenue is entirely dependent on the success of clinical trials and partnerships. This chart reflects analyst expectations, which are essentially an assessment of the scientific potential of the company's developments and their commercial prospects.
%20sales%20of%20the%20company%20ORIC%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-ORIC-Pharmaceuticals&v=1772559327027 "Schedule of future (projected) sales of the company ORIC Pharmaceuticals")
Future (projected) sales of companies in the market segment - Oncology targeted therapy
ORIC Pharmaceuticals is a biopharmaceutical company focused on overcoming cancer treatment resistance. The forecast on this chart reflects potential future revenue from their pipeline of drugs. This is an analyst's perspective on the commercial prospects of their scientific approaches to treating difficult-to-treat cancers.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-targeted-therapy&v=1772559327043 "Schedule of future (projected) sales of companies in the market segment - Oncology targeted therapy")
Future (projected) sales of the market as a whole
ORIC Pharmaceuticals is a clinical-stage biotech company focused on overcoming drug resistance in cancer treatment. Its value depends on the success of its clinical trials. This chart, reflecting stock market sentiment, influences investor risk appetite and the availability of funding for long-term oncology developments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772559327049 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality ORIC Pharmaceuticals
ORIC Pharmaceuticals is a biotechnology company focused on developing treatments for cancer resistant to existing therapies. Its current financial performance reflects significant investment in research and development. The chart shows profitability at the clinical trial stage, the success of which will determine the company's future profitability.
Market segment marginality - Oncology targeted therapy
#VALUE!
Market marginality as a whole
ORIC Pharmaceuticals is a biotech company focused on developing treatments for treatment-resistant cancer. Its funding depends on investors' willingness to invest in long-term, risky projects. This gross margin chart reflects market sentiment. High margins and economic growth create a favorable environment for raising capital in biotech.
Employees in the company, segment and market as a whole
Number of employees in the company ORIC Pharmaceuticals
ORIC Pharmaceuticals is a clinical-stage biotech company focused on cancer treatment. Its team is comprised almost entirely of scientists and clinical development specialists. The growth of its staff is a direct indicator of progress: the more drugs in clinical trials, the more experts are required to manage them.
Share of the company's employees ORIC Pharmaceuticals within the market segment - Oncology targeted therapy
ORIC Pharmaceuticals is a biotech company focused on overcoming drug resistance in cancer treatment. Its core resource at this stage is its scientific team. This chart shows the share of the company's intellectual capital dedicated to solving one of the most challenging problems in oncology, a measure of its research ambitions.
Number of employees in the market segment - Oncology targeted therapy
ORIC Pharmaceuticals is focused on developing treatments for treatment-resistant cancers. The chart showing employment in targeted oncology illustrates the intensity of research in this field. For ORIC, the growing number of scientists means accelerating scientific discovery overall, but also a fierce competition for the best minds and breakthrough molecules in one of the most competitive fields of biotech.
Number of employees in the market as a whole
ORIC Pharmaceuticals is a biopharmaceutical company focused on cancer therapy. Its headcount growth is driven by research progress and funding rounds, not by general economic cycles. It competes for specialized PhDs and clinicians within the large labor market represented by these data.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company ORIC Pharmaceuticals (ORIC)
ORIC Pharmaceuticals is a biopharmaceutical company focused on developing treatments for treatment-resistant cancer. Its entire business is built on cutting-edge science and intellectual property. This chart vividly illustrates how the market values the potential of breakthrough scientific ideas: enormous value is created by a small team of highly skilled research scientists.
%20of%20the%20company%20ORIC%20Pharmaceuticals%20(ORIC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-ORIC-Pharmaceuticals-ORIC&v=1772559327111 "Chart of market capitalization per employee (in thousands of dollars) of the company ORIC Pharmaceuticals (ORIC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
ORIC Pharmaceuticals is focused on developing drugs to combat cancer treatment resistance. In biotech, a company's value is the hope for a future breakthrough. This chart shows the enormous potential value investors place on the research of each company scientist working to solve one of the most challenging problems in oncology.
%20by%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-targeted-therapy&v=1772559327119 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology targeted therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
ORIC Pharmaceuticals is a biotech company focused on treating treatment-resistant cancer. The chart reflects its scientific potential. Currently, ORIC's entire value is derived from its research and scientific team. This indicator demonstrates how investors assess the company's development prospects relative to each member of this elite scientific team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772559327120 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company ORIC Pharmaceuticals (ORIC)
ORIC Pharmaceuticals is a biotech company focused on cancer treatment. Like many R&D-stage companies in the sector, its profits are likely negative. This chart shows how much the company invests in each scientist to advance its drugs through clinical trials. This is an indicator of research intensity, not current profitability.
%20Chart%20ORIC%20Pharmaceuticals%20(ORIC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-ORIC-Pharmaceuticals-ORIC&v=1772559327125 "Company Profit Per Employee (in thousands of dollars) Chart ORIC Pharmaceuticals (ORIC)")
Profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
ORIC Pharmaceuticals is a biotech company focused on developing cancer drugs resistant to existing treatments. Like other R&D companies, this metric is negative. It measures the "cost" of one scientist's work per year. Investors view this as an investment in breakthrough drugs that could be worth billions.
%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-targeted-therapy&v=1772559327126 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy")
Profit per employee (in thousands of dollars) for the market as a whole
ORIC Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer resistant to existing therapies. It's a classic biotech company in the R&D stage. Its entire staff consists of scientists and clinicians. There's no profit yet, only research expenses. This indicator doesn't reflect current efficiency, but rather the "cost" of one employee in the development of future blockbuster drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772559327127 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee ORIC Pharmaceuticals (ORIC)
ORIC Pharmaceuticals is a biotech company focused on overcoming drug resistance in cancer treatment. Currently in the clinical stage, it has no commercial products. This graph would show zero revenue, which is typical for R&D companies whose value is determined by the potential of their scientific developments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-ORIC-Pharmaceuticals-ORIC&v=1772559327127 "Sales chart per company employee ORIC Pharmaceuticals (ORIC)")
Sales per employee in the market segment - Oncology targeted therapy
ORIC Pharmaceuticals (ORIC) is a biotech company focused on developing treatments for cancer resistant to existing therapies. This chart shows the average revenue per employee in the sector. For a company in the R&D stage, it is important for comparing the efficiency of capital and personnel utilization with other biotech competitors.
Sales per employee for the market as a whole
ORIC Pharmaceuticals (ORIC) is a biotech company focused on developing treatments for cancer resistant to existing therapies. This metric reflects the high cost of R&D. Investors monitor it in anticipation of a breakthrough that will lead to exponential growth of the numerator.
Short shares by company, segment and market as a whole
Shares shorted by company ORIC Pharmaceuticals (ORIC)
ORIC Pharmaceuticals (ORIC) is a biotech company focused on developing treatments for cancer resistant to existing therapies. It's a quest for the "holy grail" of oncology. This chart shows the level of skepticism. The high number of short positions reflects the enormous risks: investors are betting that the company's complex scientific advances will not prove effective in clinical trials. (344)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-ORIC-Pharmaceuticals-ORIC&v=1772559327148 "Short Shares Chart for the Company ORIC Pharmaceuticals (ORIC)")
Shares shorted by market segment - Oncology targeted therapy
ORIC is an oncology company focused on developing drugs that overcome cancer resistance to existing therapies. This chart reflects the overall sentiment in the sector. It reflects investor skepticism toward biotech startups in oncology, where R&D risks are highest.
Shares shorted by the overall market
ORIC Pharmaceuticals is a clinical-stage biotech focused on oncology. Like all speculative biotechs, its shares are a bet on future success. When this overall pessimism indicator rises, investors are unwilling to wait. They are dumping unprofitable companies en masse, as they require constant refinancing for R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator ORIC Pharmaceuticals (ORIC)
ORIC Pharmaceuticals (ORIC) is an oncology company focused on developing drugs to overcome cancer resistance to therapy. This chart measures hype. It shows "overbought" (above 70) due to positive clinical trial data or "oversold" (below 30) amid delays or setbacks, which is typical for the biotech sector.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-ORIC-Pharmaceuticals-ORIC&v=1772559327153 "RSI 14 indicator chart for the company's stock ORIC Pharmaceuticals (ORIC)")
RSI 14 Market Segment - Oncology targeted therapy
ORIC Pharmaceuticals (ORIC) is an oncology company focused on developing drugs that overcome cancer cell resistance to existing therapies. This chart measures overall sentiment in the Targeted Oncology sector. It helps distinguish ORIC's development successes from the overall overheated or oversold biotech sector.
RSI 14 for the overall market
ORIC Pharmaceuticals (ORIC) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ORIC (ORIC Pharmaceuticals)
ORIC Pharmaceuticals is an oncology company focused on developing drugs that overcome cancer cell resistance to existing therapies. This chart shows the average analyst price target, which is almost entirely dependent on the success of clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ORIC-ORIC-Pharmaceuticals&v=1772559327161 "A chart showing analyst consensus forecasts for the expected stock price. ORIC (ORIC Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price ORIC (ORIC Pharmaceuticals)
ORIC Pharmaceuticals is a clinical-stage biotech company focused on developing drugs that overcome cancer resistance to existing therapies. This chart reflects analysts' speculative expectations regarding their early clinical data and scientific approach to cancer treatment.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ORIC-ORIC-Pharmaceuticals&v=1772559327162 "A chart showing the difference between the consensus forecast and the actual stock price. ORIC (ORIC Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Oncology targeted therapy
ORIC Pharmaceuticals is a biotech company focused on overcoming cancer resistance to existing treatments. This chart shows analysts' overall expectations for the targeted oncology sector. It reflects whether experts believe this complex scientific approach will be successful.
Analysts' consensus forecast for the overall market share price
ORIC Pharmaceuticals is a biotech company focused on developing cancer treatments that overcome tumor resistance to existing therapies. This chart shows overall risk appetite. For ORIC, as a clinical-stage company, overall market optimism is critical to attracting the capital needed to fund long-term research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index ORIC Pharmaceuticals
ORIC Pharmaceuticals is a biotech company attacking one of the key challenges in oncology: treatment resistance. They are developing drugs that aim to breach cancer cells' defenses when they stop responding to standard therapy. This chart is an assessment of their complex science and reflects investor expectations for clinical data from their pipeline of candidates.
AKIMA Market Segment Index - Oncology targeted therapy
ORIC Pharma (ORIC) is a clinical-stage biotech focused on oncology; the company develops innovative drugs aimed at overcoming cancer resistance to therapy. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this R&D focus on resistance (ORIC) differentiate it from the average pharmaceutical company?
The AKIM Index for the overall market
ORIC Pharmaceuticals is an oncology company developing treatments that overcome cancer resistance. It's a battle to extend patients' lives. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this clinical-stage research compares to the broader economic trends affecting biotech.
